- Data demonstrates oral PL8177 causes diseased colons to move
to a healthier state
- Provides further support for ongoing oral PL8177 Phase 2
ulcerative colitis study
CRANBURY, N.J., Oct. 16,
2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE
American: PTN), a biopharmaceutical company
developing first-in-class medicines based on molecules
that modulate the activity of the melanocortin receptor system,
today announced the presentation of a poster entitled
Cellular and Molecular Impact of the Melanocortin Receptor
Agonist PL8177 in DSS Induced Colitis in Rats at
the United European Gastroenterology Week (UEG) being held
October 14-17 2023 in Copenhagen, Denmark. Lead author Paul S. Kayne, Ph.D., Vice President Biological
Sciences at Palatin Technologies, presented the poster. The poster
is currently available on the UEG 2023 Conference website. The
poster will be available on Palatin's website
at: www.palatin.com.
"The Palatin research team continues to produce groundbreaking
data demonstrating the utility and mechanism of action of
melanocortin agonists in treating inflammatory diseases," said
Carl Spana, Ph.D., President and CEO
of Palatin. "This important mechanism of action data supports our
active business development efforts for PL8177, including continued
enrollment of patients in a Phase 2 ulcerative colitis study."
The poster presents data from a series of oral PL8177
dose-ranging studies in the DSS colon inflammation model and
includes histological, genomic, and proteomic data. Compared to
vehicle and the positive control mesalazine, PL8177 showed
significant improvements in inflamed colon health, including
relative increases in colon cells needed for a healthy colon.
PL8177 treatment showed clear evidence of resolving pathological
inflammation by repolarizing colon macrophages from a
pro-inflammatory to a pro-inflammation resolving state.
Oral PL8177 caused diseased colons to move towards a healthy
state and to resolve damaging inflammation. By resolving
inflammation rather then blocking it, PL8177 may provide efficacy
without the safety concerns of immunosuppressive treatments
for patients suffering with inflammatory bowel disease.
About PL8177
PL8177 is a synthetic cyclic heptapeptide
with demonstrated efficacy in multiple animal inflammatory bowel
disease models. PL8177 is a potent, selective agonist at the human
melanocortin-1 receptor (MC1r), with sub-nanomolar affinity binding
and EC50 functional values. Palatin data demonstrates
that their oral formulation of PL8177 was protected from
degradation in the stomach and small intestine of humans and
delivered to the colon over an extended period. In addition, orally
administered PL8177 had a significant effect on resolving
inflammation in a rat bowel inflammation model.
PL8177 in oral formulations has demonstrated repeated, robust
efficacy in ulcerative colitis disease models. MC1r is found on
epithelial cells and resident macrophages of the colon which are
accessible from the lumen of the colon. Orally administered PL8177
is not systemically absorbed. PL8177 has the potential for
excellent efficacy without safety concerns.
About Ulcerative Colitis
Ulcerative colitis is a
chronic disease of the large intestine (colon), with inflammation
and ulcerations that can cause significant abdominal pain,
persistent diarrhea, loss of appetite and other symptoms. An
estimated 1 million individuals in the
United States are affected by ulcerative colitis, with over
350,000 diagnosed with moderate-to-severe disease. Existing
treatments are not effective in a substantial portion of patients
with moderate-to-severe ulcerative colitis, with certain severe
cases resulting in surgical removal of the colon.
About Melanocortin Receptor Agonists and
Inflammation
The melanocortin receptor
("MCr") system has effects on inflammation, immune
system responses, metabolism, food intake, and sexual function.
There are five melanocortin receptors, MC1r through
MC5r. Modulation of these receptors, through use of
receptor-specific agonists, which activate receptor
function, or receptor-specific antagonists, which block receptor
function, can have medically significant pharmacological effects.
Many tissues and immune cells located throughout the body,
including the gut, kidney and eye, express melanocortin
receptors, empowering our opportunity to directly activate
natural pathways to resolve disease inflammation. Drugs based
on melanocortin agonists have been approved by the FDA
for treating several conditions, including female sexual
dysfunction, inflammatory/autoimmune diseases, and
rare forms of genetic obesity.
About Palatin
Palatin is a biopharmaceutical
company developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin receptor systems, with
targeted, receptor-specific product candidates for the treatment of
diseases with significant unmet medical need and
commercial potential. Palatin's strategy
is to develop products and then form
marketing collaborations with industry leaders to maximize their
commercial potential. For additional information regarding Palatin,
please visit Palatin's website at www.Palatin.com and follow
Palatin on Twitter at @PalatinTech.
Forward-looking Statements
Statements in this
press release that are not historical facts, including statements
about future expectations of Palatin, such as
statements about PL8177 clinical trials and results, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995. Palatin
intends that such forward-looking statements be subject
to the safe harbors created thereby. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that could cause Palatin's actual results to be materially different from its historical
results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results
may differ materially from those discussed in the forward-looking
statements for reasons including, but not limited to, results of
clinical trials, regulatory actions by the FDA and other regulatory
and the need for regulatory approvals, Palatin's
ability to fund development of its technology and establish
and successfully complete clinical trials, the length of time and
cost required to complete clinical trials and submit applications
for regulatory approvals, products developed by competing
pharmaceutical, biopharmaceutical and biotechnology companies,
commercial acceptance of Palatin's products, and other
factors discussed in Palatin's periodic filings with
the Securities and Exchange Commission. Palatin is not
responsible for updating for events that occur after the date of
this press release.
Palatin Technologies® is a registered trademarks of Palatin
Technologies, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-presents-data-at-the-united-european-gastroenterology-week-2023-conference-on-pl8177-ulcerative-colitis-treatment-301957055.html
SOURCE Palatin Technologies, Inc.